Why drug manufacturing needs to become more flexible

April 22, 2019

Digital transformation does not stop at the pharmaceutical industry. But until Pharma 4.0 can become socially acceptable, it will first and foremost be necessary to define globally uniform standards. This is going to take time. Time which the industry does not have in view of the speed of development at Google and Amazon and their penetration of the healthcare market. The White Paper gives a brief overview of the way in which structures have evolved over time and places them in the context of current technological developments in drug production.

Spotlight

Pii (Pharmaceutics International, Inc.)

Pii (Pharmaceutics International, Inc) is a multinational contract formulation development, Clinical Trial Materials (CTM), and commercial manufacturing company with corporate headquarters in Hunt Valley, Maryland, USA. Founded in 1994, Pii manufactures a wide range of dosage forms covering solid, semi-solid and aseptic filling. This service is complemented by full analytical and regulatory support.

OTHER WHITEPAPERS
news image

Optimizing the Path from Pre-Clinical to Clinical Development

whitePaper | December 22, 2022

According to research, post-pandemic R&D growth is healthy in the pharma industry with the number of drugs in the R&D pipeline now exceeding 20,000 in 2022—which represents an expansion rate of 8.22% from 2021 (1).

Read More
news image

Using High Throughput SPR to Explore the Full Kinetic and Epitope Diversity of Large Antibody Libraries

whitePaper | February 24, 2023

A new way of thinking and working has evolved for the discovery of therapeutic antibodies. Until recently, large numbers of antibodies were generated, only for a relatively small fraction to be sampled and engineered for further lead generation.

Read More
news image

Expediting early-phasedevelopment ofsmall molecules: Anintegrated approach

whitePaper | November 18, 2022

Small molecule drug development has changed substantially in recent years. With the heightened focus on molecularly targeted therapies, small molecule active pharmaceutical ingredients (APIs).

Read More
news image

Vendor Partnering in a Bioprocess Manufacturing and Supply Chain Ecosystem

whitePaper | October 14, 2022

Supply constancy, cost, sterility – even a subset of the factors that impact materials selection can be daunting for biopharmaceutical companies embarking on a new drug development project.

Read More
news image

Protein fingerprints pave the way for microarray comparison

whitePaper | June 9, 2022

Anaxomics has developed a novel method of analysis for microarray data based on the generation and subsequent comparison of 2D fingerprints for each sample. Microarray results are incorporated into a protein interaction network and embedded with all sorts of biological and medical data.

Read More
news image

Utilizing Multi-parameter Epitope Binning to Understand aTherapeutic Antibody’s Mechanism of Action

whitePaper | January 20, 2023

Understanding an antibody’s mechanism of action (MOA) is critical to its clinical success. Not only does MOA have a large impact on safety and efficacy.

Read More

Spotlight

Pii (Pharmaceutics International, Inc.)

Pii (Pharmaceutics International, Inc) is a multinational contract formulation development, Clinical Trial Materials (CTM), and commercial manufacturing company with corporate headquarters in Hunt Valley, Maryland, USA. Founded in 1994, Pii manufactures a wide range of dosage forms covering solid, semi-solid and aseptic filling. This service is complemented by full analytical and regulatory support.

Events